Ms. Jennifer Che, our President and Managing Director, spoke at the Hong Kong Intellectual Property Department’s IP Training Programme on patent commercialization and technology transfer. Since 2020, the IPD has partnered with the Vocational Training Council’s Institute of Professional Education and Knowledge to arrange various IP training programmes. Other speakers include Mr. Michael Lin – a strategic business consultant & President of IIPCC, Dr. David Ai from the London School of Economics and Political Science, and Dr. Vincent Zhong, an expert in IP licensing and technology transfer who worked at Netac Technology Co., Ltd.

Jennifer’s talk, titled ‘Building a Strategic Patent Portfolio for Commercialization,’ taught professionals how to strategically build patent portfolios with a business mindset. Aside from building IP, Jennifer also focused on topics such as IP licensing, ownership transfers, enforcement, and cross-border issues.

Attendees, including IP owners and executives from startups, SMEs, and large enterprises in the innovation sector, found her talk incredibly insightful and beneficial.

We are very thankful to the IPD and PEAK/VTC for this opportunity to help build a deeper understanding of IP and commercialization in Hong Kong.

Our Past Events

Recommended Insights

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

12 April 2023
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

China Releases Draft Examination Guidelines for the new Patent Law

4 December 2020
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

1 April 2025
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
Top crossarrow-right